business / news / / CNBC
U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion.
Eli Lilly is in advanced negotiations to acquire Kelonia Therapeutics for over $2 billion.
KEY POINTS
- The deal may include milestone-based additional payments linked to Kelonia's clinical progress.
- An acquisition announcement could occur as soon as Monday, per The Wall Street Journal.
- Kelonia specializes in clinical-stage genetic medicines, with a focus on CAR-T cell therapies.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →